ANIK vs. CERS, OSUR, UTMD, ATRI, NVRO, LUNG, SKIN, PLSE, TCMD, and GUTS
Should you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Atrion (ATRI), Nevro (NVRO), Pulmonx (LUNG), Beauty Health (SKIN), Pulse Biosciences (PLSE), Tactile Systems Technology (TCMD), and Fractyl Health (GUTS). These companies are all part of the "surgical & medical instruments" industry.
Cerus (NASDAQ:CERS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
In the previous week, Anika Therapeutics had 3 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Anika Therapeutics and 2 mentions for Cerus. Anika Therapeutics' average media sentiment score of 0.80 beat Cerus' score of -0.40 indicating that Cerus is being referred to more favorably in the media.
78.4% of Cerus shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 7.1% of Cerus shares are owned by company insiders. Comparatively, 5.9% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cerus has higher earnings, but lower revenue than Anika Therapeutics. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cerus has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Cerus received 268 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 64.38% of users gave Anika Therapeutics an outperform vote.
Cerus presently has a consensus price target of $3.83, indicating a potential upside of 94.59%. Anika Therapeutics has a consensus price target of $29.50, indicating a potential upside of 16.14%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cerus is more favorable than Anika Therapeutics.
Cerus has a net margin of -19.27% compared to Cerus' net margin of -45.39%. Cerus' return on equity of 0.48% beat Anika Therapeutics' return on equity.
Summary
Cerus beats Anika Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Anika Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anika Therapeutics Competitors List
Related Companies and Tools
